Bimekizumab sustains ACR50 edge over risankizumab in PsA at week 24
Week 24 Phase 3b data show bimekizumab had an 11.1-point numerical ACR50 advantage over risankizumab in 553 adults with active PsA, while skin clearance converged.
Topic
Head To Head Trial
Topic